Applications and optimization of immunization procedures

ILAR Journal

Volumn 46, Issue 3, 2005, Pages 241-257

  Schunk, Michael K ^a   Macallum, G Eileen ^b  

^a SANOFI PASTEUR   (France)

^b Sanofi Pasteur   (Canada)

Author keywords

Adjuvant; Animal research; Antibody; Disease; Immunity; Immunization; Vaccine

Indexed keywords

ANTITOXIN; BCG VACCINE; CANCER VACCINE; CHOLERA VACCINE; DENDRITIC CELL VACCINE; DIPHTHERIA TOXOID; DNA VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLIXIMAB; INFLUENZA VACCINE; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 6 ANTIBODY; LIVE VACCINE; MONOCLONAL ANTIBODY; OKT 3; ORAL POLIOMYELITIS VACCINE; PEPTIDE; PNEUMOCOCCUS VACCINE; POLYCLONAL ANTIBODY; RABIES VACCINE; TOXOID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TYPHOID VACCINE; VACCINE; VENOM ANTISERUM;

ALLERGY; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BIRTH CONTROL; BLADDER CANCER; BOTULISM; CANCER; CANCER PREVENTION; CELLULAR IMMUNITY; CHOLERA; CLINICAL PROTOCOL; CLINICAL TRIAL; COCAINE DEPENDENCE; DIAGNOSTIC VALUE; DIPHTHERIA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL ANIMAL; FERTILITY; GRAFT REJECTION; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; INFLAMMATORY DISEASE; INFLUENZA; LEUKOCYTE; MELANOMA; NONHUMAN; POLIOMYELITIS; QUALITY CONTROL; RABIES; REVIEW; RHEUMATOID ARTHRITIS; SNAKEBITE; STREPTOCOCCUS INFECTION; TETANUS; TOBACCO DEPENDENCE; TYPHOID FEVER; VACCINE PRODUCTION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; NICOTIANA TABACUM; PNEUMOCOCCUS; STREPTOCOCCUS;

EID: 21044447400     PISSN: 10842020     EISSN: None     Source Type: Journal    
DOI: 10.1093/ilar.46.3.241     Document Type: Review

References (131)

1. Afek A, Gearge J, Gilburd B, Rauova L, Goldberg I, Kopolovic J, Harats D, Shoenfeld Y. 2000. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 14:115-121.
2. Aitken RJ, Paterson M, van Duin M. 1996. The potential of the zona pellucida as a target for immunocontraception. Am J Reprod Immunol 35:175-180.
3. Akkermans AM, Hendriksen CF, Marsman FR, van de Donk HJ. 1996. Evaluation and validation of a single-dilution potency assay based upon serology of vaccines containing diphtheria toxoid: Analysis for consistency in production and testing. Dev Biol Stand 86:323-324.
4. Alving CR. 2002. Design and selection of vaccine adjuvants: Animal models and human trials. Vaccine 20:S56-S64.
5. Andreakos E, Taylor PC, Feldmann M. 2002. Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Biotechnol 13:615-620.
6. Arnon R, Ben-Yedidia T. 2003. Old and new vaccine approaches. Int Immunopharmacol 2:1195-1204.
7. Augustinova H, Hoeller D, Yao F. 2004. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol 78:5756-5765.
8. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. 2004. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113:998-1007.
9. Berry LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, Gockel CM, Beagley KW. 2004. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 72:1019-1028.
10. Breeling JL, Onderdonk AB, Cisneros RL, Kasper DL. 1988. Bacteroides vulgatus outer membrane antigens associated with carrageenan-induced colitis in guinea pigs. Infect Immun 56:1754-1759.
11. Brindle RJ, Morris CA, Berger R, Kurtz JB. 1994. Inadequate response to intradermal hepatitis A vaccine. Vaccine 12:483-484.
12. Bunn T Dietert R, Ladics S, Holsapple M. 2001. Developmental immunotoxicology assessment in the rat: Age, gender, and strain comparisons after exposure to lead. Toxicol Methods 11:41-58.
13. Burdin N. 2005. Targeting innate immunity with adjuvants: Can accurate danger signals drive more protective immune responses? In: Moingeon PH, ed. Frontiers in the Development of New Vaccines. Norwich UK: Horizon Scientific Press Ltd (In Press).
14. Carrera MR, Ashely JA, Wirsching P, Koob GF, Janda KD. 2001. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci U S A 98:1988-1992.
15. CDER [Center for Drug Evaluation and Research]. 2002. Guidance for Industry: Imunotoxicology Evaluation of investigational New Drugs. US Department of Health and Human Services, Food and Drug Administration. Washington DC: GPO.
16. Cerny EH, Levy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, Patiny L, Tuchscherer G, Cerny T. 2002. Preclinical development of a vaccine "against smoking." Onkologie 25:406-411.
17. Chande C, Thakar YS, Pande S, Dhanvijay AG, Shrikhande AV, Saoji AM. 1996. Sequential study of IgG antibody response in immunized rabbit and development of immunization protocol for raising monospecific antibody. Ind J Pathol Microbiol 39:27-32.
18. Chen D, Colditz IG, Glenn GM, Tsonis CG. 2002. Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep. Vet Immunol Immunopathol 86:177-182.
19. Chiocchia G, Manoury B, Boissier MC, Fournier C. 1993. T cell-targeted immunotherapy in murine collagen-induced arthritis. Clin Exp Rheumatol 11:S15-S17.
20. Chong CS, Cao M, Wong WW, Fischer KP, Addison WR, Kwon GS, Tyrrell DL, Samuel J. 2005. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Controlled Release 102:85-99.
21. Coghlan LG, Hanausek M. 1990. Subcutaneous immunization of rabbits with nitrocellulose paper strips impregnated with microgram quantities of protein. J Immunol Methods 129:135-138.
22. Conroy RM, LoBuglio AF, Curiel DT. 1996. Polynucleotide-mediated immunization therapy of cancer. Semin Oncol 23:135-147.
23. Costa O, Divoux D, Ischenko A, Tron F, Fontaine M. 2003. Optimization of an animal model of experimental autoimmune encephalomyelitis achieved with a multiple Mog35-55 peptide in C57BL6/J strain of mice. J Autoimmun 20:51-61.
24. Davis HL, McCluskie MJ. 1999. DNA vaccines for viral diseases. Microbes Infect 1:7-21.
25. de Groot J, Ruis MA, Scholten JW, Koolhaas JM, Boersma WJ. 2001. Long-term effects of social stress on antiviral immunity in pigs. Physiol Behav 73:145-158.
26. Delves PJ, Lund T, Roitt IM. 2002. Antifertility vaccines. Trends Immunol 23:213-219.
27. Diekman AB, Herr JC. 1997. Sperm antigens and their use in the development of an immunocontraceptive. Am J Reprod Immunol 37:111-117.
28. Doherty TM, Olsen AW, van Pinxteren L, Andersen P. 2002. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect Immun 70:3111-3121.
29. El-Aneed A. 2004. Current strategies in cancer gene therapy. Eur J Pharmacol 498:1-8.
30. Ericksson K, Holmgren J. 2002. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14:666-672.
31. Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, Garcia Z, Michel ML, Jack RW, Jung G, Kosmatopoulos K, Mateo L, Suhrbier A, Lemonnier FA, Langlade-Demoyen P. 1999. H-2 class I knockout, HLA-A2.1-transgenic mice: A versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 29:3112-3121.
32. Gerdts V, Snider M, Brownlie R, Babiuk LA, Griebel PJ. 2002 Oral DNA vaccination in utero induces mucosal immunity and immune memory in the neonate. J Immunol 168:1877-1885.
33. Gockel CM, Bao S, Beagley KW. 2000. Transcutaneous immunization induces mucosal and systemic immunity: A potent method for targeting immunity to the female reproductive tract. Mol Immunol 37:537-544.
34. Gockel CM, Bao S, Holland MK, Beagley KW. 2003. Influence of the murine oestrous cycle on the induction of mucosal immunity. Am J Reprod Immunol 50:369-379.
35. Gomber S, Sharma R, Ramachandran VG. 2004. Immunogenicity of low dose intradermal hepatitis B vaccine and its comparison with standard dose intramuscular vaccination. Ind Pediatr 41:922-926.
36. Gore ER, Gower J, Kurali E, Sui J, Bynum J, Ennulat D, Herzyk DJ. 2004. Primary antibody response to keyhole limpet hemocyanin in rat as a model for immunotoxicity evaluation. Toxicology 197:23-25.
37. Griffin JFT. 2002. A strategic approach to vaccine development: Animal models, monitoring vaccine efficacy, formulation and delivery. Adv Drug Deliv Rev 54:851-861.
38. Gupta PN, Mishra V, Jain S, Dubey PK, Vyas SP. 2004. Topical immunization: Mechanistic insight and novel delivery systems. Ind J Biotechnol 3:9-21.
39. Guthman MD, Britton, RJ, Carnero AJ, Gabri MR, Cinat G, Koliren L, Lewi D, Fernandez LE, Alonso DF, Gomez DE, Fainboim L. 2004. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: A report on safety and immunogenicity. J Immunother 27:442-451.
40. Gutowski JK, Weksler ME. 1982. Studies on the syngeneic mixed lymphocyte reaction. I. The ontogeny of the syngeneic mixed lymphocyte reaction in mice. Immunology 46:727-736.
41. Hammond SA, Cook SJ, Falo Jr. LD, Issel CJ, Montelaro RC. 1999. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology 254:37-49.
42. Hanke T, McMichael A. 1999. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol Lett 66:177-181.
43. Hanly WC, Artwohl JE, Bennett BT. 1995. Review of polyclonal antibody production procedures in mammals and poultry. ILAR J 37:93-118.
44. Harandi AM, Holmgren J. 2004. CpG DNA as a potent inducer of mucosal immunity: Implications for immunoprophylaxis and immunotherapy of mucosa infections. Curr Opin Invest Drugs 5:141-145.
45. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch FM, Gao XM, Takiguchi M, Greenwood BM, Townsend AR, McMichael AM, Whittle HC. 1992. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360:434-439.
46. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. 2003. Mucosal immunisation and adjuvants: A brief overview of recent advances and challenges. Vaccine 21:S89-S95.
47. Hosono M, Fujiwara M, Katsura Y. 1986. Age related change of spleen cells participating in MHC-homozygous F1 anti-parent mixed lymphocyte reactions. Dev Comp Immunol 10:585-595.
48. Houdebine LM. 2002. Antibody manufacture in transgenic animals and comparisons with other systems. Curr Opin Biotechnol 13:625-629.
49. Hu JG, Kitagawa T. 1990. Studies on the optimal immunization schedule of experimental animals. VI. Antigen dose-response of aluminum hydroxide-aided immunization and booster effect under low antigen dose. Chem Pharm Bull (Tokyo) 38:2775-2779.
50. Hu JG, Yokoyama T, Kitagawa T. 1990. Studies on the optimal immunization schedule of experimental animals. IV. The optimal age and sex of mice, and the influence of booster injections. Chem Pharm Bulletin (Tokyo) 38:448-451.
51. Israel ZR, Gettie A, Ishizaka ST, Mishkin EM, Staas J, Gilley R, Montefiori D, Marx PA, Eldridge JH. 1999. Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques. AIDS Res Hum Retrovir 15: 1121-1136.
52. John M, Bridges EA, Miller AO, Calderwoon SB, Ryan ET. 2002. Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. Vaccine 20:2720-2726.
53. Johnston SA, Tang DC. 1994. Gene gun transfection of animal cells and genetic immunization. Methods Cell Biol 43 Pt A:353-365.
54. Jourdier TM, Boudet F, Boucaud N, Perrier-Michon MI, Gregoire V, Ramirez L, Rossignol D, Gautier V, Rossin D, Thenadey M, Hessler C, De Montfort A, Burdin N, Moste C. 2005. [Comparative study of the immune response to vaccine antigens in mice and guinea pigs originating from different breeders.] [In French]. Sci Tech Anim Lab (In Press).
55. Kantak KM. 2003. Vaccines against drugs of abuse: A viable treatment option? Drugs 63:341-352.
56. Kataoka M, Toyoizumi H, Yamamoto A, Ochiai M, Horiuchi Y. 2002. Chinese hamster ovary (CHO) cell clustering does not correlate with in vivo histamine - Sensitization when measuring residual activity of aldehyde-treated pertussis toxin (PT). Biologicals 30:297-302.
57. Kazanji M, Tartablia J, Franchini G, de Thoisy B, Talarmin A, Contamin H, Gessain A, de The G. 2001. Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus). J Virol 75:5939-5948.
58. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB. 2002. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97-138.
59. Kellermann SA, Green LL. 2002. Antibody discovery: The use of transgenic mice to generate monoclonal antibodies for therapeutics. Curr Opin Biotechnol 13:593-597.
60. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. 2004. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351:2330-2332.
61. Kim KW, Kim SH, Jang JH, Lee EY, Park SW, Um JH, Lee YJ, Lee CH, Yoon S, Seo SY, Jeong MH, Lee ST, Chung BS, Kang CD. 2004a. Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class 1-mediated antitumor immunity. Cancer Immunol Immunother 53:315-322.
62. Kim KW, Kim SH, Shin JG, Kim GS, Son YO, Park SW, Kwon BH, Kim DW, Lee CH, Sol MY, Chung BS, Kang CD. 2004b. Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. Int J Cancer 109:685-690.
63. Klaasen HL, Van der Heijden PJ, Stok W, Poelma FG, Koopman JP, Van den Brink ME, Bakker MH, Eling WM, Beynen AC. 1993. Apathogenic, intestinal, segmented, filamentous bacteria stimulate the mucosal immune system of mice. Infect Immun 61:303-306.
64. Konno A, Utsuyama M, Kurashima, C, Kasai M, Kimura S, Hirokawa K. 1993. Effects of a protein-free diet or food restriction on the immune system of Wistar and Buffalo rats at different ages. Mech Ageing Dev 72:183-197.
65. Kassouf W, Kamat AM. 2004. Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 4:1037-1046.
66. Krzych U, Thurman GB, Goldstein AL, Bressler JP, Strausser HR. 1979. Sex-related immunocompetence of BALB/c mice. I. Study of immunologic responsiveness of neonatal, weanling, and young adult mice. J Immunol 123:2568-2574.
67. Ku G, Kronenberg M, Peaacock DJ, Tempst P, Banquerigo ML, Braun BS, Reeve JR Jr, Brahn E. 1993. Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen. Eur J Immun 23:591-599.
68. Kutzler MA, Weiner DB. 2004. Developing DNA vaccines that call to dendritic cells. J Clin Invest 114:1334-1342.
69. Lehmann D, Pomat WS, Riley ID, Alpers MP. 2003. Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea. Vaccine 21:3446-3450.
70. Li H, Zhang YY, Sun YN, Huang XY, Jia YF, Li D. 2004. Induction of systemic lupus erythematosus syndrome in BALB/c mice by immunization with active chromatin. Acta Pharmacologica Sinica 25:807-811.
71. Lima KM, Aparecida dos Santos A, Rodrigues Jr. JM, Silva CL. 2004. Vaccine adjuvant: It makes the difference. Vaccine 22:2374-2379.
72. Lin H, Wang LF, Song JL, Xie YM, Yang QM. 2002. Effect of dietary supplemental levels of vitamin A in the egg-laying production and immune responses of heat-stressed laying hens. Poult Sci 81:458-465.
73. Luber-Narod J, Austin-Ritchie T, Banner B, Hollins C 3rd, Maramag C, Price H, Menon M. 1996. Experimental autoimmune cystitis in the Lewis rat: A potential animal model for interstitial cystitis. Urol Res 24:367-373.
74. Lyerly HK. 2003. Quantitating cellular immune responses to cancer vaccines. Semin Oncol 30:9-16.
75. Marchant A, Newport M. 2001. Prevention of infectious diseases by neonatal and early infantile immunization: Prospects for the new millennium. Inf Dis Clin Pract 10:199-204.
76. Mawas F, Peyre M, Beignon AS, Frost L, Del Giudice G, Rappuoli R, Muller S, Sesardic D, Paridos CD. 2004. Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate - Cross-reacting material. Vaccine 190: 1177-1182.
77. McGuirk P, Mills KHG. 2002. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 23:450-455.
78. McMurray DN, Yetley EA. 1982. Immune responses in malnourished guinea pigs. J Nutr 112:167-174.
79. Melo ME, Gabaglia CR, Moudgil KD, Sercarz EE, Quinn A. 2002. Strain-dependent effect of nasal instillation of antigen on the immune response in mice. Israel Med Assoc J 4:902-907.
80. Methner U. 2001. The use of animal models in the development of classical vaccines. In: Schmidt A, Weber OF, eds. Animal Testing in Infectiology. Contributions to Microbiology. Vol 9. Basel: Karger. p 58-70.
81. Metz B, Hendriksen CF, Jiskoot W, Kersten G. 2002. Reduction of animal use in human vaccine quality control: Opportunities and problems. Vaccine 20:2411-2430.
82. Miner NA, Koehler J, Greenaway L. 1969. Intraperitoneal injection of mice. Appl Microbiol 17:250-251.
83. Mitchison NA. 1972. Dose, frequency and route of administration of antigen. In: Borek F, ed. Immunogenicity. New York: American Elsevier Publishing Co., Inc. p 87-109.
84. Moingeon P. 2001. Cancer vaccines. Vaccine 19:1305-1326.
85. Moingeon P, de Taisne C, Almond J. 2002. Delivery technologies for human vaccines. Br Med Bull 62:29-44.
86. Moreau M. 1999. [A new vaccine concept: Polysaccharide conjugate vaccines.] [In French]. Ann Pharm Fr 57:223-231.
87. Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD. 1993. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp 160 and recombinant gp 160. Proc Natl Acad Sci U S A 90:2443-2447.
88. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. 1986. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A 83:7443-7446.
89. Nichols KL, Bauman SK, Schafer FB, Murphy JW. 2002. Differences in components at delayed-type hypersensitivity reaction sites in mice immunized with either a protective or a nonprotective immunogen of Cryptococcus neoformans. Infect Immun 70:591-600.
90. Nilsson BO, Larsson A. 1990. Intrasplenic immunization with minute amounts of antigen. Immunol Today 11:10-12.
91. O'Hagan DT, Valiante NM. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev 2:727-735.
92. Orand MG, Widgren EE, Sivashanmugam P, Richardson RT, Hall SH, French FS, VandeVoort CA, Ramachandra SG, Ramesh V, Jagannadha Rao A. 2004. Reversible immunocontraception in male monkeys immunized with eppin. Science 306:1117.
93. O'Rourke J, Lee A, McNeill J. 1988. Differences in the gastrointestinal microbiota of specific pathogen free mice: An often unknown variable in biomedical research. Lab Anim 22:297-303.
94. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, Salio M, Van Pel A, Man S, Bonin E, Liljestrom P, Dunbar PR, Cerundolo V. 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168: 4391-4398.
95. Partidos CD. 2003. Delivering vaccines into the skin without needles and syringes. Expert Rev Vaccines 2:753-761
96. Peri BA, Rothberg RM. 1981. Circulating antitoxin in rabbits after ingestion of diptheria toxoid. Infect Immun 32:1148-1154.
97. Pickard KM, Bremnar AR, Gordaon JN, MacDonald TT. 2004. Microbial-gut interactions in health and disease. Immune responses. Best Pract Res Clin Gastroenterol 18:271-285.
98. Pink JR, Kieny MP. 2004. 4th Meeting on Novel Adjuvants Currently in/Close to Human Clinical Testing. World Health Organization - Organisation Mondiale de la Sante Fondation Merieus, Annecy, France, 23-25 June 2003. Vaccine 22:2097-2102.
99. Puaux AL, Marsac D, Post S, Singh M, Earl P, Moss B, Le Grand R, Riviere Y, Michel ML. 2004. Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles. Vaccine 22: 3535-3545.
100. Ramsay AJ, Leong KH, Ramshaw IA. 1997. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol Cell Bio 75:382-388.
101. Rethy LA, Geresi M, Rethy L. 2001. Age- and sex-determined differences in the establishment of tetanus antitoxin production in guinea-pigs. Acta Veterinaria Hungarica 49:25-30.
102. Rocha CD, Caetano BC, Machado AV, Bruna-Romero O. 2004. Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 7:83-94.
103. Sanderson SD, Cheruku SR, Padmanilayam MP, Vennerstrom JL, Thiele GM, Palmatier MI, Bevins RA. 2003. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 3:137-146.
104. Schwartz M, Kipnis J. 2004. A common vaccine for fighting neurodegenerative disorters: Recharging immunity for homeostasis. Trends Pharmacol Sci 25:407-412.
105. Sela M, Arnon R, Schechter B. 2002. Therapeutic vaccines: Realities of today and hopes for the future. Drug Discov Today 7:664-673.
106. Serody JS, Collins EJ, Tisch RM, Kuhns JJ, Frelinger JA. 2000. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J Immunol 64:4961-4967.
107. Sesardic D, Dawes CS, McLellan K, Durrani Z, Yost SE, Corbel MJ. 1999. Non-pertussis components of combination vaccines: Problems with potency testing. Biologicals 27:177-181.
108. Shaw FE Jr, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, Roehm RR Jr, Talley WS, Hadler SC. 1989. Effect of anatomic injection site, age and smoking of the immune response to hepatitis B vaccination. Vaccine 7:425-430.
109. Sheridan JF, Eydelloth RS, Vonderfecht SL, Aurelian L. 1983. Virus-specific immunity in neonatal and adult mouse rotavirus infection. Infect Immun 39:917-927.
110. Silverman E, Drazen JM. 2003. Immunostimulatory DNA for asthma: Better than eating dirt. Am J Cell Mol Biol 28:645-647.
111. Slifka MK, Ahmed R. 1996. Long-term humoral immunity against viruses: Revisiting the issue of plasma cell longevity. Trends Microbiol 4:394-400.
112. Standfast AF. 1958. The comparison between field trials and mouse protection tests against intranasal and intracerebral challenges with Bordetella pertussis. Immunology 1:135-143.
113. Stinissen P, Zhang J, Medaer R, Vandevyver C, Raus J. 1996. Vaccination with autoreactive T cell clones in multiple sclerosis: Overview of immunological and clinical data. J Neurosci Res 45:500-511.
114. Stohr K, Meslin FX. 1997. Zoonoses and fertility control in wildlife - Requirements for vaccines. Reprod Fertil Dev 9:149-155.
115. Sueno T, Inoue E, Singh DP, Awata T, Chylack LT Jr., Shinohara T. 1997. Oral administration of lens homogenate suppresses antibody production in mice injected with beta-crystallin emulsified in CFA. Exp Eye Res 64:379-385.
116. Swain BK, Johri TS, Majumdar S. 2000. Effect of supplementation of vitamin E, selenium and their different combinations on the performance and immune response of broilers. Br Poult Sci 41:287-292.
117. Tellier MC, Pu R, Pollock D, Vitsky A, Tartaglia J, Paoletti E, Yamamoto JK. 1998. Efficacy evaluation of prime-boost protocol: Canarypox virus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats. AIDS 12:11-18.
118. Tearina Chu TH, Halverson GR, Yazdanbakhsh K, Øyen R, Reid ME. 2001. A DNA-based immunization protocol to produce monoclonal antibodies to blood group antigens. Br J Haematol 113:32-36.
119. Teuber SS, del Val G, Morigasaki S, Jung HR, Eisele PH, Frick OL, Buchanan BB. 2002. The atopic dog as a model of peanut and tree nut allergy. J Allergy Clin Immunol 110:921-927.
120. Tierney R, Beignon AS, Rappuoli R, Muller S, Sesardic D, Partidos CD. 2003. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J Infect Dis 188:753-758.
121. Tuting T, Storkus WJ, Falo LD Jr. 1998. DNA immunization targeting the skin: Molecular control of adaptive immunity. J Invest Dermatol 111: 183-188.
122. Van Oudenaren A, Haaijman JJ, Benner R. 1984. Frequencies of background cytoplasmic Ig-containing cells in various lymphoid organs of athymic and euthymic mice as a function of age and immune status. Immunology 51:735-742.
123. Wakabayashi A, Utsuyama M, Hosoda T, Sato K, Hirokawa K. 1999. Differential age effect of oral administration of an antigen on antibody response: An induction of tolerance in young mice but enhancement of immune response in old mice. Mech Ageing Dev 109:191-201.
124. Walker C, Zuany-Amorium C. 2001. New trends in immunotherapy to prevent atopic diseases. Trends Pharmacol Sci 22:84-90.
125. Walters CS, Claman HN. 1975. Age-related changes in cell-mediated immunity in BALB/C mice. J Immunol 115:1438-1443.
126. Wang QM, Sun SH, Hu ZL, Xiao CJ, Zhang JC. 2004. Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine 22:3622-3627.
127. Ward MDW, Madison SL, Andrews DL, Sailstad DM, Gavett SH, Selgrade MJK. 2000. Comparison of respiratory responses to Metarhizium anisopliae extract using two different sensitization protocols. Toxicology 147:133-145.
128. Wilkie B, Mallard B. 1999. Selection for high immune response: An alternative approach to animal health maintenance? Vet Immunol Immunopathol 72:231-235.
129. Willbanks GA, Rootman DS, Jay V, Wiggert B, Chamberlain J, Inman RD. 1997. Experimental autoimmune uveitis in HLA-B27 transgenic mice. Hum Immunol 53:188-194.
130. Wolochok JD, Livingston PO. 2001. Vaccines for melanoma: Translating basic immunology into new therapies. Lancet Oncol 2:205-211.
131. Zhao J, Li D, Piao X, Yang W, Wang F. 2002. Effects of vitamin C supplementation on performance, iron status and immune function of weaned piglets. Arch Tierernahr 56:33-40.